Lovastatin as Treatment for Neurocognitive Deficits in Neurofibromatosis Type 1: Phase I Study - 09/09/11
, Peter G. Kardel, MA a, Karin S. Walsh, PsyD a, b, Kenneth N. Rosenbaum, MD a, Gerard A. Gioia, PhD b, Roger J. Packer, MD b
Communications should be addressed to: Dr. Acosta; Department of Neurology; Jennifer and Daniel Gilbert Neurofibromatosis Institute; Children’s National Medical Center; 111 Michigan Avenue NW; Washington, DC 20010.Abstract |
In a neurofibromatosis type 1 murine model, treatment with lovastatin reversed cognitive disabilities. We report on a phase I study examining the safety and tolerability of lovastatin in children with neurofibromatosis type 1. Twenty-four children with neurofibromatosis type 1 underwent a dose-escalation protocol for 3 months to identify the maximum tolerated dose and potential toxicity. Minimal side effects were evident, and no child experienced dose-limiting toxicity. Cognitive evaluations were completed before and after treatment, and the results suggested improvement in areas of verbal and nonverbal memory. Additional analyses, using reliable change indices, indicated improvements exceeding those of test-retest or practice effects in some participants. These observations may be analogous to the improvements observed in a neurofibromatosis type 1 murine model treated with lovastatin, although further study and replication are required. The safety and preliminary cognitive results support the need for a larger phase II trial in this population.
Le texte complet de cet article est disponible en PDF.Plan
Vol 45 - N° 4
P. 241-245 - octobre 2011 Retour au numéro
Article précédent
- Cerebrospinal Fluid Opening Pressure in Children: Experience in a Controlled Setting
- Marcus W. Lee, Vettakikoru V. Vedanarayanan
- Clinical Neuroimaging Features and Outcome in Molybdenum Cofactor Deficiency
- Kayal Vijayakumar, Rox Gunny, Stephanie Grunewald, Lucinda Carr, Kling W. Chong, Catherine DeVile, Robert Robinson, Niamh McSweeney, Prab Prabhakar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?